Vedolizumab in the treatment of inflammatory bowel diseases
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha1. LF UK v Praze
Published in:
Kardiol Rev Int Med 2016, 18(2): 137-140
Overview
Vedolizumab is a monoclonal IgG1 antibody, which has been approved a few months ago for use in clinical practice in the European Union for Crohn´s disease and ulcerative colitis patients. It is expected to be introduced in the Czech market this year. The clinical research GEMINI I-III proved that vedolizumab is very effective in patients with moderate to severe ulcerative colitis and Crohn’s disease. The big advantage of vedolizumab therapy is its high efficacy in patients who fail or stop to respond to an anti-TNFα therapy, a sustained effect that increases over time, low immunogenicity and a high safety profile, caused by a high selectivity for the gastrointestinal tract. Possible disadvantages may include a relatively slow onset of the anti-inflammatory effect, limited influence on symptoms outside the bowel and a low potential for the treatment of perianal Crohn’s disease.
Keywords:
vedolizumab – Crohn’s disease – ulcerative colitis – biological treatment
Sources
1. Bortlík M. Vedolizumab – nová antiintegrinová protilátka s vysokou gastrointestinální selektivitou. Gastroent Hepatol 2014; 68: 481– 482. doi:10.14735/ amgh2014481.
2. Raine T. Vedolizumab for inflammatory bowel disease: changing the game, or more of the same? United European Gastroenterol J 2014; 5: 333– 344. doi: 10.1177/ 2050640614550672.
3. Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction and maintenace therapy for ulcerative colitis. N Engl J Med 2013; 369: 699– 710. doi: 10.1056/ NEJMoa1215734.
4. Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711– 721. doi: 10.1056/ NEJMoa1215739.
5. Sanborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005; 353: 1912– 1925.
6.Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patinets with Crohn’s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014; 147: 618– 627. doi: 10.1053/ j.gastro.2014.05.008.
7. Lukáš M. Biologická léčba idiopatických střevních zánětů. In: Pavelka K, Arenberger P, Lukáš M et al (eds). Biologická léčba zánětlivých autoimunitních onemocnění v revmatologii, gastroenterologii a dermatologii. Praha: Grada Publishing 2014.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2016 Issue 2
Most read in this issue
- Fixed-dose combinations in dyslipidemy treatment
- Sacubitril-valsartan (LCZ696) in the treatment of heart failure
- Fixed-dose combination therapy for hypertension
- Fixed-dose combination in pulmonology